Stock research
Healthcare · Biotechnology
Basis: Adjusted daily closes.
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases.
Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.
Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies